The public offer documents are available in Swedish when no translation exists.

2022-12-21

Appilcation Form for subscription of shares without rights

2022-02-10

Company description

2021-09-27

Application form for subscription of shares through the exercise of warrants (Swedish)

2020-08-25

Teaser


Inbjudan till teckning av units

2019-10-28

Anmälningssedel

2019-10-23

Villkor för teckningsoptioner


Inbjudan till teckning av Units i Chordate Medical


Teaser Företrädesemission oktober 2019

2019-04-03

Anmälningssedel för teckning av units i Chordate utan företrädesrätt

2019-03-22

Villkor och anvisningar


Teaser

2018-05-09

Inbjudan till teckning av Units i Chordate Medical maj 2018 – Teaser


Inbjudan till teckning av Units i Chordate Medical Företrädesemission maj 2018 – Memorandum

2017-03-02

Listningsmemorandum inför notering på NGM Nordic MTF Chordate Medical

2017-01-31

Inbjudan till teckning av aktier i Chordate Medical Holding


Välkommen att teckna aktier i Chordate Notering på NGM Nordic MTF – Emissionsfolder

Investor relations

2022-12-21

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the treatment Ozilia™ Migraine, which is based on Kinetic Oscillation Stimulation, a technique for treating rhinitis and migraine. We have a patent on Ozilia™ in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact